NCT05281263View on ClinicalTrials.gov

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

December 5, 2022

Study Completion Date

May 3, 2023

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

CPI-RSV-F Vaccine (BLB-201)

see arm/group description

Trial Locations (2)

29405

Coastal Carolina Research Center, North Charleston

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Blue Lake Biotechnology Inc.

INDUSTRY

NCT05281263 - Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults | Biotech Hunter | Biotech Hunter